A Bright Opportunity for Growth

EXPERIENCE OPTILIGHT BY LUMENIS

Sponsored Content

Lumenis Vision is renowned for technological breakthroughs with a long list of industry gold standards.
Introducing OptiLight, the first and only light therapy for dry eye management. Using the patented
Optimal Pulse Technology™, it offers a safe, targeted, and effective treatment supported by over fifty
clinical studies.

Dry eye disease is a common disorder that causes dry, gritty, burning, tired eyes and fluctuating vision.
About sixteen million Americans have been diagnosed, 1 and twice as many may be undiagnosed with dryeye. MGD is the leading cause of dry eye disease, accounting for about 86% of cases.

The Lumenis multi-center, double-blinded, randomized controlled FDA trial showed that Lumenis IPL
with patented Optimal Pulse Technology (OPT TM ) significantly improved tear breakup time, meibum
quality, and meibomian gland expressibility. 3 The clinical trial joins a long list of studies of Lumenis’ IPL
with OPTTM that have shown the same results, as well as reduction of inflammatory markers. 4-7

Experience firsthand, the safe, precise, elegant procedure you want and the comfortable, effective
therapy your patients need to manage dry eye disease.

“Personally, I don’t think I can practice in a dry eye practice without having OptiLight”, said Dr. Douglas
K. Devries, “Because if you’re missing this level of technology, you will know you’re just not offering
everything for your patients.”

OptiLight is a quick, in-office treatment that can elevate and scale your practice while significantly
improving your patients’ signs of dry eyes. Explore how OptiLight ™ can enhance dry eye management
for you and your patients by joining our upcoming webinar with Corporate Optometry featuring Dr.
James Deom.

Why OptiLight with OPT TM Technology?
We have helped thousands of Optometrists across the country, with OptiLight contributing meaningfully to practice profitability while delivering results for hundreds of thousands of patients suffering from Dry Eye Disease.

We are committed to your success with enhanced clinical training and robust marketing support.
Lumenis, as your partner, is working diligently to raise awareness among patients, driving them to seek
medical professionals who can offer OptiLight. By partnering with influencers such as Candice King,
Ashley Tisdale and Jamie Chung who talk about OptiLight in mass media, this highly effective treatment
is gaining great exposure.

Citations
1. Farrand et al. Am J Ophthalmol 2017;182:90-98.
2. Lemp MA et al. (2012) Cornea May;31(5):472-8.
3. FDA study sponsored by Lumenis: internal reference LUM-VBU-M22-IPL-17-01. 4. Yan et al. (2020), Eye & Contact Lens 2021, 27(1):45-53.
5. Arita et al. (2019) Ocul Surf 17(1):308-13.
6. Gao et al. (2019) Int J Ophthalmol 12(11):1708-1713.
7. Liu et al. (2017) Am J Ophthalmol 183:81-90.